Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Internet and telecommunications group SoftBank took part in the round, which will fund the business finance provider's acquisition strategy.

Deutsche Telekom Capital Partners invested in a series D round for the call centre technology provider led by Goldman Sachs Asset Management.

Sanofi Ventures co-led replacement therapy developer Glycomine's latest round, which included Novo, Asahi Kasei Pharma Ventures and Chiesi Ventures.

Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.

Sheng Ye Capital and existing investor So-Young participated in a round for the medical supplies ordering platform sized at a minimum of $70m.

Eli Lilly, Johnson & Johnson and Pfizer helped drug developer TRexBio close its $59m series A round while Slack backed human resources software provider Oyster at a $475m valuation.

The Novel Group, PayPal and Qualcomm-backed digital financial services provider was valued at $7.4bn in its latest funding round.

The autonomous vehicle technology developer has disclosed it raised $310m in its latest round, which included corporate joint venture Alliance Ventures.

HubSpot and Salesforce both participated in a series D round which boosted the enterprise software marketplace's overall funding to $257m.